カテゴリ： GlobalData, 企業調査, 韓国

Hanmi Pharmaceuticals Co Ltd (128940)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Hanmi Pharmaceuticals Co Ltd (128940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014191
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：66
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：韓国
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Hanmi Pharmaceuticals Co Ltd (Hanmi Pharma), a subsidiary of Hanmi Science Co Ltd is a developer of prescription drugs and over the counter drugs. The company’s prescription drugs include osteoporosis, antibiotics, antidiarrheal, liver supplements and antiemetics. It provides over the counter products such as vitamins, nutritional supplements and calcium supplement, among others. Hanmi Pharma’s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others. The company operates through its manufacturing facilities located in Hwaseong, Songpa, and Pyeongtaek, South Korea. Hanmi Pharma is headquartered in Seoul, South Korea.

Hanmi Pharmaceuticals Co Ltd (128940) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Licensing Agreements 22
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Genentech to Enter into Licensing Agreement with Hanmi Pharma 23
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 24
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 25
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 26
Kinex Pharma Expands Licensing Agreement with Hanmi Pharma for Orascovery Program 27
Hanmi Pharma Enters into Licensing Agreement with Kinex Pharma for KX01 28
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 29
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 30
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 31
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 32
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 33
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 34
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 36
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 37
Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 38
Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 40
Acquisition 41
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 41
Hanmi Pharmaceuticals Co Ltd – Key Competitors 42
Hanmi Pharmaceuticals Co Ltd – Key Employees 43
Hanmi Pharmaceuticals Co Ltd – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
Feb 05, 2016: Hanmi Pharmaceutical’s sales reach record high of W1.3175 trillion 45
Product News 46
06/17/2016: Hanmi Presented the Research Results of HM-12525A Long Acting Diabetes-Obesity Medicine at American Diabetes Association meeting 46
06/02/2016: Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib 47
03/31/2017: Spectrum Pharmaceuticals Announces Presentation of Abstract on ROLONTIS (eflapegrastim) at the AACR 49
Product Approvals 50
May 17, 2016: South Korea is first to approve next generation lung cancer treatment olmutinib (BI 1482694 / HM61713) 50
Jan 25, 2016: Athenex Announces US FDA Allowance of the Investigation New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel 51
Clinical Trials 52
May 05, 2017: Hanmi Pharmaceutical Announced IND Approval of HM95573, a Novel Oral RAF inhibitor 52
Apr 04, 2017: Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTIS (eflapegrastim) at the American Association for Cancer Research (AACR) Annual Meeting 53
Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations 54
Jan 06, 2017: Hanmi presents pan-RAF inhibitor preclinical trial results at Europe Cancer Symposium 55
Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer 56
Dec 05, 2016: Spectrum Pharmaceuticals Highlights Four Abstracts on ROLONTIS (eflapegrastim) at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016 57
Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016 59
Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016 60
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO 61
Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug Olmutinib at ASCO 62
Jun 05, 2016: New data on olmutinib (BI 1482694) presented at ASCO 2016 underscores clinical potential of Boehringer Ingelheim’s next generation lung cancer compound 63
Mar 07, 2016: Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor 64
Jan 29, 2016: Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Hanmi Pharmaceuticals Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Hanmi Pharmaceuticals Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Hanmi Pharmaceuticals Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Cell>Point And Hyun IMC Expand Licensing Agreement To Include Hanmi Pharma For Cancer And Heart Disease Imaging 13
Hanmi Pharma Enters into Co-Development Agreement with Innovent Biologics 15
Serenus Biotherapeutics Enters into Co-Marketing with Hanmi Pharma 16
Hanmi Pharma Enters into Co-Marketing Agreement with Novartis Korea 17
Hanmi Pharma Enters into Co-promotion Agreement with Merck Sharp & Dohme Korea 18
Kainos Medicine Enters into Co-Development Agreement with Hanmi Pharm 19
Hanmi Pharma Enters Into Co-Marketing Agreement With Sanofi-Aventis For Ibestin 20
Hanmi Pharma Enters Into Co-Development Agreement With GlaxoSmithKline For EBF Products 21
Sanofi Enters into Licensing Agreement with Hanmi Pharma 22
Genentech to Enter into Licensing Agreement with Hanmi Pharma 23
Zai Lab Enters into Licensing Agreement with Hanmi Pharma 24
Spectrum Pharma Enters into Licensing Agreement with Hanmi Pharma for Poziotinib 25
Spectrum Pharma Enters Into Licensing Agreement With Hanmi Pharma For SPI-2012 26
Kinex Pharma Expands Licensing Agreement with Hanmi Pharma for Orascovery Program 27
Hanmi Pharma Enters into Licensing Agreement with Kinex Pharma for KX01 28
Janssen Pharma to Enter into Licensing Agreement with Hanmi Pharma 29
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 30
Allegro Ophthalmics Enters into Licensing Agreement with Hanmi Pharma for Luminate 31
Hanmi Pharm Enters into Licensing Agreement with Luye Pharma for Poziotinib 32
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 33
Kinex Pharma Expands Licensing Agreement With Hanmi Pharma 34
Amneal Pharma Enters Into Licensing Agreement With Hanmi Pharma For Nexium Alternative 36
Hanmi Pharma Enters Into Licensing Agreement With AngioLab For Anti-Obesity Botanical Drug 37
Kinex Pharma Enters Into Licensing Agreement With Hanmi Pharma 38
Hanmi Pharma Expands Licensing Agreement With Merck For Amosartan 40
Hanmi Pharma to Invest USD20 Million in Allegro Ophthalmics 41
Hanmi Pharmaceuticals Co Ltd, Key Competitors 42
Hanmi Pharmaceuticals Co Ltd, Key Employees 43
Hanmi Pharmaceuticals Co Ltd, Other Locations 44
Hanmi Pharmaceuticals Co Ltd, Subsidiaries 44

★海外企業調査レポート[Hanmi Pharmaceuticals Co Ltd (128940)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Chronos Therapeutics Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Chronos Therapeutics Ltd (Chronos) is a developer of medications for degenerative and behavioural diseases of the brain and nervous system. The company offers research and development, screening, discovery, repositioning and acquisition programs. Its pipeline products comprise RDC5 neurodege …
  • Hero MotoCorp Ltd：戦略・SWOT・企業財務分析
    Hero MotoCorp Ltd - Strategy, SWOT and Corporate Finance Report Summary Hero MotoCorp Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Oaks Hotels & Resorts Limited：企業の戦略・SWOT・財務分析
    Oaks Hotels & Resorts Limited - Strategy, SWOT and Corporate Finance Report Summary Oaks Hotels & Resorts Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Lenzing AG (LNZ)：企業の財務・戦略的SWOT分析
    Lenzing AG (LNZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • InvitroCue Ltd (IVQ)-製薬・医療分野：企業M&A・提携分析
    Summary InvitroCue Ltd (InvitroCue), formerly Bunuru Corporation Ltd is a provider of bio-analytic solutions. The company offers digital pathology services such as digitization, sample preparation, staining, computer aided diagnosis and consultation, telepathology, automated reporting and image arch …
  • Indian Bank：企業の戦略・SWOT・財務情報
    Indian Bank - Strategy, SWOT and Corporate Finance Report Summary Indian Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • NeuroBo Pharmaceuticals Inc (NRBO)：企業の財務・戦略的SWOT分析
    NeuroBo Pharmaceuticals Inc (NRBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • EyePoint Pharmaceuticals Inc (PSDV)：企業の製品パイプライン分析2018
    Summary EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. Its durasert …
  • BTA Bank JSC：企業の戦略・SWOT・財務情報
    BTA Bank JSC - Strategy, SWOT and Corporate Finance Report Summary BTA Bank JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • GW Pharmaceuticals Plc (GWP)：医療機器：M&Aディール及び事業提携情報
    Summary GW Pharmaceuticals Plc (GW Pharmaceuticals) is a biopharmaceutical company that discovers, develops and commercializes novel therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the …
  • Trinity Industries, Inc.：企業の戦略・SWOT・財務分析
    Trinity Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Trinity Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Panasonic Homes Co., Ltd.：企業の戦略的SWOT分析
    Panasonic Homes Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Invicta Holdings Limited：企業の戦略・SWOT・財務情報
    Invicta Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Invicta Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Danaher Corporation (DHR)-医療機器分野：企業M&A・提携分析
    Summary Danaher Corporation (Danaher) is a medical technology company which designs, manufactures and markets medical, professional, commercial and industrial products and services. The company offers a wide range of testing instruments, communications solutions, water quality systems, medical diagn …
  • Mazda Motor Corporation：企業の戦略・SWOT・財務分析
    Mazda Motor Corporation - Strategy, SWOT and Corporate Finance Report Summary Mazda Motor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)-製薬・医療分野：企業M&A・提携分析
    Summary Tianjin Zhongxin Pharmaceutical Group Corp Ltd (TZPG) manufactures and markets traditional Chinese medicine, western medicine and health products. The company offers Chinese patent medicines, Chinese medicinal materials, western medicines, dietary supplements, pharmaceutical raw materials an …
  • AccentCare Inc：企業の戦略的SWOT分析
    AccentCare Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Slovnaft AS (1SLN01AE)：企業の財務・戦略的SWOT分析
    Slovnaft AS (1SLN01AE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Delta Electronics (Thailand) Public Company Ltd. (DELTA)：企業の財務・戦略的SWOT分析
    Delta Electronics (Thailand) Public Company Ltd. (DELTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company …
  • iiNet Limited：企業の戦略・SWOT・財務情報
    iiNet Limited - Strategy, SWOT and Corporate Finance Report Summary iiNet Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆